iQure has formed a research partnership with University of Padova associate professor Laura Civiero to investigate iQ-007, the company's lead programme targeting EAAT2, the transporter responsible for glutamate uptake.
AeroRx Therapeutics has secured $21m in Series A financing, led by Avalon BioVentures, with participation from Alexandria Venture Investments, Correlation Ventures, and other investors.
The US Food and Drug Administration (FDA) has awarded Fast Track designation to Alto Neuroscience’s ALTO-101, a novel small molecule phosphodiesterase-4 (PDE4) inhibitor for the treatment of cognitive impairment linked to schizophrenia (CIAS).
BioLineRx and Hemispherian have formed a joint venture to advance the development of GLIX1, an oral small molecule aimed at targeting DNA damage response in glioblastoma (GBM) and other types of cancer.
Argo Biopharmaceutical has received investigational new drug (IND) approval from the National Medical Products Administration (NMPA) of China for a Phase II clinical trial of BW-40202 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
Dewpoint Therapeutics has secured funding in a Series D funding round, which will support the progression of DPTX3186, a condensate modulator (c-mod), into clinical studies by 2025-end.
Novonesis and Novo Nordisk have formed a research partnership to investigate the role of the gut microbiome in sustaining metabolic health.
Eli Lilly has received the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, an investigational KRAS G12C inhibitor.
OMass Therapeutics in the UK has signed an exclusive collaboration and licensing agreement with Roche Group member Genentech to develop and commercialise inflammatory bowel disease (IBD) therapies.
Biosynth, a supplier of essential raw materials and services for the life sciences and diagnostics sectors, has opened an expanded good manufacturing practice (GMP) bioconjugation facility at its Berlin site in Germany.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.